Tacrine

Tacrine
Clinical data
Trade names	Cognex
AHFS/Drugs.com	Monograph
MedlinePlus	a693039
Pregnancy; category	AU: C;
Routes of; administration	Oral, rectal
ATC code	N06DA01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	2.4–36% (oral)
Protein binding	55%
Metabolism	Hepatic (CYP1A2)
Elimination half-life	2–4 hours
Excretion	Renal
Identifiers
	IUPAC name 1,2,3,4-Tetrahydroacridin-9-amine;
CAS Number	321-64-2 ;
IUPHAR/BPS	6687;
DrugBank	DB00382 ;
ChemSpider	1859 ;
UNII	4VX7YNB537;
ChEBI	CHEBI:45980 ;
ChEMBL	ChEMBL95 ;
PDB ligand	THA (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID1037272 ;
ECHA InfoCard	100.005.721
Chemical and physical data
Formula	C13H14N2
Molar mass	198.269 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	183 °C (361 °F)
Boiling point	358 °C (676 °F)
	SMILES n1c3c(c(c2c1cccc2)N)CCCC3;
	InChI InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15) ; Key:YLJREFDVOIBQDA-UHFFFAOYSA-N ;
	(verify)

Tacrine is a centrally acting acetylcholinesterase inhibitor and indirect cholinergic agonist (parasympathomimetic). It was the first centrally acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was marketed under the trade name Cognex. Tacrine was first synthesised by Adrien Albert at the University of Sydney in 1949. It also acts as a histamine N-methyltransferase inhibitor.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.